Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Urticaria Market From 2025 To 2029?
The market scale for urticaria has experienced a prompt expansion in the past few years. It is projected to escalate from $4.03 billion in 2024 to $4.76 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 18.1%. Factors contributing to the historic phase growth include increased instances of allergies, elevated awareness regarding skin diseases, advanced developments in immunology and biologics, heightened demand for antihistamines, and advancements in diagnostic methods.
In the coming years, the urticaria market size is projected to witness a rapid increase, expected to reach$9.14 billion in 2029″ with a compound annual growth rate (CAGR) of 17.7%. The anticipated growth in this timeframe can be ascribed to the escalating number of chronic urticaria cases, the widespread acceptance of biologic therapies, growth in dermatology research funding, wider access to cutting-edge allergy diagnostic tools, and an increase in customized medicine creation. Key trends for the forecast period encompass AI-enabled diagnostic instruments, the creation of new biologics, advancements in personalized immunotherapy, wearable devices for skin monitoring, and the application of telemedicine in allergy management.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23554&type=smp
What External and Internal Drivers Are Contributing to the Growth of theUrticaria Market?
The rise in the consciousness and treatment of skin disorders is anticipated to bolster the urticaria market’s expansion. The escalation in pollution results in a surge in skin allergies and diseases, fueling the need for enlightenment and sophisticated treatments. Urticaria aids in emphasizing skin ailment mindfulness and medical intervention by displaying immune system reactions, propelling research, improving diagnostics, and developing specific treatments. For example, The Skin Cancer Foundation, a nonprofit organization based in the US, noted in February 2024, that 1 in 5 Americans are diagnosed with skin cancer by the time they are 70, with more than 2 deaths happening every hour in the U.S. This underscores the immediate necessity for precautionary actions, as experiencing five or more sunburns can double the chances of melanoma. Hence, the rise in skin disease awareness and treatment is propelling the urticaria market’s growth.
What Segment Types Define the Urticaria Market Structure?
The urticariamarket covered in this report is segmented –
1) By Type: Acute Urticaria; Chronic Urticaria
2) By Drug Class: Antihistamines; Anti-inflammation Medications; Antidepressants; Monoclonal Antibodies; Other Drug Classes
3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Acute Urticaria: Allergic Urticaria; Infectious Urticaria; Drug-Induced Urticaria; Contact Urticaria
2) By Chronic Urticaria: Chronic Spontaneous Urticaria (CSU); Chronic Inducible Urticaria (CIndU)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23554&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Urticaria Market?
North America was the largest region in the urticaria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Urticaria Market?
Key players in the urticaria market are aggressively pursuing the development of advanced solutions like mast cell inhibitor antibodies, aimed at enhancing therapeutic outcomes for chronic spontaneous urticaria through the targeting of mast cell activation. These mast cell inhibitor antibodies, essentially targeted monoclonal antibodies, work by preventing the activation or degranulation of mast cells by obstructing particular receptors or signaling pathways, hence decreasing allergic reactions, inflammation, and other mast cell-triggered conditions. For example, in May 2024, Allakos Inc., a biotech company based in the United States, started a Phase 1 clinical trial for AK006, a promising therapy model for the treatment of chronic spontaneous urticaria (CSU). AK006 has a dual targeting feature: it impacts both IgE-dependent and IgE-independent mast cell activation pathways, extending its efficacy to patients unresponsive to antihistamines or prior biologic treatments. With the targeted inhibition of mast cell activity via the Siglec-6 receptor, AK006 endeavours to offer a more holistic and durable solution for managing CSU, signifying a crucial step forward in urticaria treatment and immunotherapy research.
View the full report here:
https://www.thebusinessresearchcompany.com/report/urticaria-global-market-report
What Is the Definition of the Urticaria Market?
Urticaria, commonly known as hives, is a skin condition characterized by red, itchy, and raised welts. It occurs due to an allergic reaction, stress, or unknown triggers, leading to histamine release. The condition can be acute (lasting less than six weeks) or chronic (persisting longer). Treatment includes antihistamines, avoiding triggers, and, in severe cases, corticosteroids or immunotherapy.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23554
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model